Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terbinafine in Chronic Hepatitis B
NCT06295328Phase 2Recruiting
- Sponsor
- University of Amsterdam
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Terbinafine in Chronic Hepatitis B (CHB) (4 arms), sponsored by University of Amsterdam. Primary endpoints: Change in level of serum HBsAg at 10 weeks and Change in serum HBV DNA at 10 weeks. Started Apr 2022; status: recruiting.
02
Drugs
Terbinafine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06295328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295328.